Cargando…

Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies

OBJECTIVE: Patients with major depressive disorder (MDD) with inadequate response to antidepressant treatment (ADT) may suffer a prolonged loss of functioning. This review aimed to determine if self-rated functional measures are informative in randomized placebo-controlled studies of adjunctive ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weiller, Emmanuelle, Weiss, Catherine, Watling, Christopher P, Edge, Christopher, Hobart, Mary, Eriksson, Hans, Fava, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751804/ https://www.ncbi.nlm.nih.gov/pubmed/29343962 http://dx.doi.org/10.2147/NDT.S146840

Ejemplares similares

Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability: Post Hoc Analysis of 2 Pivotal Clinical Studies
por: Fava, Maurizio, et al.
Publicado: (2017)

Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale
por: Hobart, Mary, et al.
Publicado: (2018)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
por: Thase, Michael E, et al.
Publicado: (2018)

PS152. Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: Meta-analysis of two pivotal studies
por: Eriksson, Hans, et al.
Publicado: (2016)

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Fava, Maurizio, et al.
Publicado: (2018)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori L., et al.
Publicado: (2016)

Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning
por: Fava, Maurizio, et al.
Publicado: (2016)

Real-World Determinants of Adjunctive Antipsychotic Prescribing for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants: A Case Review Study
por: McIntyre, Roger S., et al.
Publicado: (2015)

PS151. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori, et al.
Publicado: (2016)

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies
por: Weiss, Catherine, et al.
Publicado: (2018)

Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study
por: Lepola, Ulla, et al.
Publicado: (2018)

Understanding the emotions of patients with inadequate response to antidepressant treatments: results of an international online survey in patients with major depressive disorder
por: Mago, Rajnish, et al.
Publicado: (2018)

Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo
por: Gomeni, Roberto, et al.
Publicado: (2023)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
por: Hobart, Mary, et al.
Publicado: (2019)

Efficacy of Gemfibrozil as an Adjunct to Sertraline in Major Depressive Disorder, A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial
por: Zandifar, Atefeh, et al.
Publicado: (2021)

PS155. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies
por: Nelson, Craig, et al.
Publicado: (2016)

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study
por: Sanacora, Gerard, et al.
Publicado: (2017)

Double‐blind, randomized, placebo‐controlled pilot study of the phosphodiesterase‐3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder
por: Abdallah, Mahmoud S., et al.
Publicado: (2021)

Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study
por: Fleischhacker, W. Wolfgang, et al.
Publicado: (2016)

Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study
por: Amr, Mostafa, et al.
Publicado: (2013)

Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder
por: Papakostas, George I., et al.
Publicado: (2008)

Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2019)

Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study
por: Savitz, Adam, et al.
Publicado: (2021)

Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial
por: Dean, Olivia May, et al.
Publicado: (2014)

A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder
por: Plank, Julia R., et al.
Publicado: (2022)

Evaluation of Opioid Modulation in Major Depressive Disorder
por: Ehrich, Elliot, et al.
Publicado: (2015)

Measuring Response to Adjunctive Therapy Among Individuals with Major Depressive Disorder
por: Forma, Felicia, et al.
Publicado: (2022)

Open-label placebos as adjunctive therapy for patients with depression
por: Schienle, Anne, et al.
Publicado: (2022)

Adjunctive Bright Light Therapy for Non-Seasonal Major Depressive Disorder: A Randomized Controlled Trial
por: Chen, I-Peng, et al.
Publicado: (2022)

Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial
por: Cooper, Crystal M., et al.
Publicado: (2019)

Efficacy of physical activity in the adjunctive treatment of major depressive disorders: preliminary results
por: Pilu, Alessandra, et al.
Publicado: (2007)

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
por: Vieta, Eduard, et al.
Publicado: (2019)

The Ethics of Prescription of Placebos to Patients with Major Depressive Disorder
por: Chua, Shun-Jie, et al.
Publicado: (2015)

Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial
por: Guimarães, Mara C., et al.
Publicado: (2021)

Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder
por: Freeman, Marlene P., et al.
Publicado: (2016)

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study
por: De Berardis, Domenico, et al.
Publicado: (2020)

Are Child and Adolescent Responses to Placebo Higher in Major Depression than in Anxiety Disorders? A Systematic Review of Placebo-Controlled Trials
por: Cohen, David, et al.
Publicado: (2008)

Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder
por: Clayton, Anita H., et al.
Publicado: (2020)

Are old-old patients with major depression more likely to relapse than young-old patients during continuation treatment with escitalopram?
por: Lyketsos, Constantine G, et al.
Publicado: (2011)

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies
por: Fava, Maurizio, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h8cq4eb3ibetl1v23pnale6oja